High levels of phosphorylated m-TOR expression in HPV-related cancers can serve as a prognostic marker for poor chemotherapy response and overall patient survival, and mTOR inhibitors, such as rapamycin, are currently being tested as potential therapeutic targets [110,111,112]. Here, MTOR is linked to cancer.